Acrivon Therapeutics reported fourth quarter and full year 2025 financial results with net loss of $19.0 million and $77.9 million, respectively, and cash of $118.6 million as of December 31, 2025, expected to fund operations into Q2 2027. Highlights include ACR-368 Phase 2b data showing 52% cORR in serous endometrial cancer subjects and initiation of Arm 3 with plans for Arm 4.
Key takeaways
Net loss Q4 2025: $19.0 million vs $22.8 million in Q4 2024
Net loss FY 2025: $77.9 million vs $80.6 million in FY 2024
Cash, cash equivalents and marketable securities: $118.6 million as of Dec 31, 2025, funding into Q2 2027
ACR-368 Phase 2b cORR 52% (N=23) in serous EC subjects with ≤2 prior LoT
Initiated Arm 3 (ACR-368 + ULDG) in serous EC all-comer subjects ≤2 prior LoT
Plans to initiate Arm 4 (ACR-368 monotherapy) in serous EC all-comer subjects H1 2026
Completed exploratory Arm 2 (ACR-368 + ULDG in BM- subjects ≤3 prior LoT), objectives achieved